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Background: Dengue virus (DENV) is an arthropod borne ﬂa-
ivirus responsible of a major viral re-emergent disease in tropical
nd sub-tropical countries, affecting about50millionpeople at year
round the world. In Colombia dengue outbreaks occurs every ﬁve
r six year, but the infection is endemic and constantly reported in
ost of the country. During the last year, Colombia went through
he largest dengue epidemic occurred in decades, with 157.152
ases notiﬁed, 217 deaths conﬁrmed and all four viral serotypes
o-circulating.
Methods: Samples from two fatal cases (serum fromonepatient
nd tissue from the other one) were tested by RT-PCR using sepa-
ate dengue type speciﬁc primers.
Results: Gel electrophoresis demonstrated ampliﬁcation with
wodifferent serotypes (DENV2/DENV3andDENV2/DENV4respec-
ively). Results were conﬁrmed by sequence of the ampliﬁed
ragments and further analysis in theBasic Local Alignement Search
ool (BLAST).
Conclusion: Although the co-circulation of all 4 dengue
erotypes is common in highly endemic areas, concurrent infection
ith 2 different serotypes remains as a very unusual event. This is
he ﬁrst report of dengue co-infection in fatal cases in Colombia.
evertheless, the role of concurrent infection in severity of the
isease should be further established.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.312
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reviewof laboratory-conﬁrmed cases of humanparainﬂuenza
iruses in Kenya (2007-2011)
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USAMRU-K, Nairobi, Kenya
Background: Human parainﬂuenza viruses (HPIVs) account for
large percentage of pediatric respiratory infections, including
pper respiratory tract infections (URTIs), laryngotracheobronchi-
is (croup), bronchiolitis, and pneumonia. HPIV is the major cause
f croup (type 1 is most frequent, followed by type 3 and type 2).
uman parainﬂuenza viruses are divided into 4 types, all of whichnfectious Diseases 16S (2012) e2–e157
are classiﬁed as paramyxoviruses. Infections from types 1 and 3
account for most disease.
In May 2007 through an existing inﬂuenza surveillance net-
work, the Kenyan National Inﬂuenza center started screening for
Parainﬂuenza Viruses.
Methods:Nasopharyngeal swab specimenswere collected from
consenting patients ≥ 2 months old meeting the WHO ILI Case
deﬁnitionand transported to theKenyanNICwhere theywere inoc-
ulated into LLC-MK2 cell line. After observing cells for Cytopathic
effect, sampleswere analyzed by direct immunoﬂuorescence assay
(IFA) performed using the Respiratory Panel I Viral Screening and
Identiﬁcationkit (Chemicon International, Inc.), following theman-
ufacturer’s instructions, for detecting antigens of HPIV-1, 2 and
3.
Results: A total of 15,540 samples of nasopharyngeal swabs
were collected from July 2006 -October 2011. Respiratory
pathogens were detected in 3, 432 cases representing 22.1% and
801 (23.3%) were HPIV. HPIV- 3 was the most frequent detected
type among HPIV-positive cases accounting for 361 (45.0%) cases;
HPIV-1 and HPIV-2 were detected in 296 (37.0%) cases and 144
(18.0%) cases respectively. Analyses of co-infection pairs showed
that HPIV and FLUAV are the most common paired viruses with
HPIV3having the highest number; 28 cases followedbyHPIV1with
a total of total number of 9 cases. There were only 2 co-infections
with HPIV and pH1N1; one with HPIV- 1 and the other with HPIV2
both occurring in the year 2010. Overall, 30 cases were positive for
human parainﬂuenza 1, 2 & 3.
Conclusion: This study emphasizes the importance of contin-
ued surveillance of HPIV and reinforces the need to diagnose these
infections to provide data that are useful in control efforts and vac-
cine trials especially in developing countries where none of these
data exists. A close scrutiny of the seasonality of HPIV in Kenya will
be very vital for effective prevention and control strategies.
http://dx.doi.org/10.1016/j.ijid.2012.05.313
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Low Methicillin Resistant Staphylococcus aureus (MRSA) colo-
nization among HIV positive patients attending an outpatient
clinic in Sungai Buloh Hospital, Malaysia
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Background: Methicillin Resistant Staphylococcus aureus
(MRSA) is a multi-drug resistant bacterium which can cause a
variety of conditions from mild to life-threatening skin and soft
tissue infections. MRSA colonizers are prone to develop infections.
The colonization rates in the general population vary from < 1%
in Northern Europe to > 40% in Southern and Western Europe.
In the United States, HIV positive patients were found to have a
6-fold increase in MRSA colonization rates when compared with
non-HIV infected patients. To date, there is no published data on
MRSA screening among HIV patients in this country. The purpose
of this study is to determine the rates of MRSA colonization among
HIV positive patients in our population.
